v3.8.0.1
Income Taxes - Additional Information (Detail) - USD ($)
 12 Months Ended
Sep. 30, 2017
Sep. 30, 2016
Sep. 30, 2015
Income Tax Disclosure [Line Items]      
U.S. federal statutory tax rate 35.00% 35.00% 35.00%
Increase (Decrease) in deferred tax assets $ 665,000 $ (2,500,000) $ 348,000
Excess tax benefits (shortfalls) related to stock based compensation expense (200,000) 600,000  
Excess tax benefit from stock-based compensation plans     432,000
Deferred tax asset valuation allowance $ 4,511,000 3,847,000  
Net operating loss carryforwards, remaining period 10 years    
Unrecognized tax benefits excluding interest and penalties that would impact effective tax rate $ 1,200,000 1,200,000 900,000
Liability for unrecognized tax benefits to change significantly in the next 12 months 500,000 600,000 $ 600,000
Undistributed earnings in foreign subsidiaries 0 0  
State [Member]      
Income Tax Disclosure [Line Items]      
Net operating loss carryforwards $ 200,000    
Net operating loss carryforwards, begening of expiration year 2022    
Ireland and Luxembourg [Member] | Creagh Medical Ltd [Member]      
Income Tax Disclosure [Line Items]      
Net operating loss carryforwards $ 3,000,000    
R&D Credit Carryforwards [Member] | Federal and Minnesota [Member]      
Income Tax Disclosure [Line Items]      
Tax credit carryforwards $ 300,000    
Tax credit carryforward, begening of expiration year 2029    
In Vitro Diagnostics [Member]      
Income Tax Disclosure [Line Items]      
Capital losses generated   7,500,000  
Increase (Decrease) in deferred tax assets   $ (2,600,000)